Clinical trial

Safety and Effectiveness of ABM-168 in Adults with Advanced Solid Tumors.

NCT05831995

StatusTERMINATED

Study typeINTERVENTIONAL

Start date2023-03-30

PhasePHASE1

Study timeline

Study start (actual)2023-03-30Date precision: day

Registry last updated2024-12-06

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Advanced Solid Tumorunresolved

RAS Mutationunresolved

RAF Mutationunresolved

NF1 Mutationunresolved

Interventions

ABM-168DRUG

Sponsors & collaborators

ABM Therapeutics Corporationlead sponsor

Mapped research locations

HoustonTexas, United States1 San FranciscoCalifornia, United States1 IndianapolisIndiana, United States1 Salt Lake CityUtah, United States1 New BrunswickNew Jersey, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT05831995 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.